On Monday, Boston biopharma Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT (xanomeline-trospium), its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
https://www.pharmalive.com/wp-content/uploads/2022/08/BioSpacebrainpuzzle8-8-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-08 10:11:502022-08-08 11:27:46Karuna's Phase III data could lead to new class of drug for schizophrenia
